Investigation of granulomatous prostatitis incidence following intravesical BCG therapy.
@article{Balasar2014InvestigationOG, title={Investigation of granulomatous prostatitis incidence following intravesical BCG therapy.}, author={Mehmet Balasar and Metin Doğan and Abdulkadir Kandemir and Hakan Hakkı Taşkapu and Faruk Çiçekçi and Hatice Toy and Recai Gurbuz}, journal={International journal of clinical and experimental medicine}, year={2014}, volume={7 6}, pages={ 1554-7 } }
UNLABELLED
In the present manuscript, we studied the incidence of granulomatous prostatitis in the prostatectomy specimen of the patients who underwent transurethral resection of the prostate (TURP) after superficial bladder cancer treatment with intravesical Bacillus Calmette-Guerin (BCG) and were diagnosed with benign prostate hyperplasia (BPH). The clinical data and histopathological specimen records of 472 patients who underwent TUR-P due to BPH diagnosis, obtained over a period of 6 years…
17 Citations
Granulomatous Prostatitis After Intravesical Bacillus Calmette-Guérin Instillation Therapy: A Potential Cause of Incidental F-18 FDG Uptake in the Prostate Gland on F-18 FDG PET/CT in Patients with Bladder Cancer
- Medicine, BiologyNuclear Medicine and Molecular Imaging
- 2015
BCG-induced granulomatous prostatitis can be a potential cause of benign F-18 FDG uptake, especially in those with a history of bladder cancer treated with BCG, and the intensity of prostate uptake is decreased on the follow-up PET/CT without any treatment.
[Bladder Rupture during Intravesical BCG Therapy : A Case Report].
- MedicineHinyokika kiyo. Acta urologica Japonica
- 2018
Thinning ofthe bladder wall, delayed wound healing caused by 2 TURs, and abdominal pressure may have been the factors leading to the bladder rupture in addition to inflammation of the bladder due to BCG instillation.
Managing the adverse events of intravesical bacillus Calmette–Guérin therapy
- MedicineResearch and reports in urology
- 2015
Recommendations on the management of complications arising from intravesical treatment with bacillus Calmette–Guérin (BCG) for nonmuscle-invasive bladder tumors are provided.
Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
- MedicineJournal of oncology
- 2019
The literature on the potential complications after intravesical BCG immunotherapy for bladder cancer is reviewed and an overview on the incidence, diagnosis, and treatment modality of genitourinary and systemic BCG-induced complications is provided.
Intravesical-BCG as an Unusual Cause of Elevated PSA Leading to an Elusive Diagnosis
- Medicine
- 2021
In recent times mpMRI become an important tool to determine the need for prostate biopsy in cases of biochemical or clinical suspicion for CaP, and it seems that histological granulomatous prostatitis occurs frequently after BCG instillations as demonstrated on 75% of 119 cases.
Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy
- Medicine, PsychologyInternational Journal of Clinical Oncology
- 2017
Asymptomatic abnormal prostate findings incidentally detected by CT after BCG therapy are not rare, and these disappear over time during the follow-up period without any treatment.
Analysis of risk factors for post-bacillus Calmette–Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer
- MedicineScientific Reports
- 2020
Body mass index and prostate volume may be clinical predictors of prostate lesions after bacillus Calmette–Guerin exposure.
Comparison of Abnormal Prostate MRI and Histopathology of Prostatic Biopsy after Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer
- Medicine
- 2020
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.
References
SHOWING 1-10 OF 19 REFERENCES
Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy.
- MedicineUrology
- 1997
Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer.
- MedicineThe Journal of urology
- 1988
Granulomatous prostatitis on needle biopsy.
- MedicineArchives of pathology & laboratory medicine
- 1997
While NSGP is the most common granulomatous prostatitis seen on needle biopsy, bacillus Calmette-Guerin granulomas are not seen infrequently and may also histologically mimic carcinoma.
Toxicity of intravesical BCG and its management in patients with superficial bladder tumors
- MedicineCancer
- 1987
Toxicity of bacillus Calmette‐Guerin (BCG) Pasteur strain, given in a dose of 120 mg once a week for 6 weeks, was retrospectively evaluated in a study of 107 patients with recurrent superficial bladder cancer, suggesting that immunosuppression is a relative contraindication to BCG use.
Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations.
- MedicineThe Journal of urology
- 1990
The clinical spectrum of granulomatous prostatitis: a report of 200 cases.
- MedicineThe Journal of urology
- 1987
Granulomatous prostatitis: distinction among allergic, nonspecific, and post-transurethral resection lesions.
- MedicineHuman pathology
- 1984
Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.
- Medicine, BiologyCancer control : journal of the Moffitt Cancer Center
- 2000
A case of disseminated BCG infection causing pneumonitis that required corticosteroids and antitubercular therapy for cure is reported, and it is reported that the majority of patients tolerate BCG intravesicular treatments well.
Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin
- Medicine, BiologyAnnals of Clinical Microbiology and Antimicrobials
- 2008
In the patient who developed peritonitis, intravesical Bacillus Calmette-Guérin therapy was recommenced after antituberculosis treatment, and completed without further complications.
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.
- Medicine, BiologyThe Journal of urology
- 1992